Trending

Lantern Pharma, Inc (NASDAQ: LTRN) Shares are Pushing Upward on News of FDA Authorization to Initiate Phase 2 of their Clinical Trial. The Stock is up over 18% at the Time of this Post.


Lantern Pharma Receives FDA Authorization to Initiate its Phase 2 Clinical Trial, Harmonic, for LP-300 in Never Smokers with Non-Small Cell Lung Cancer

https://www.businesswire.com/news/home/20220714005308/en/Lantern-Pharma-Receives-FDA-Authorization-to-Initiate-its-Phase-2-Clinical-Trial-Harmonic%E2%84%A2-for-LP-300-in-Never-Smokers-with-Non-Small-Cell-Lung-Cancer

RelatedNews

Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SIGN UP FOR OUR NEWSLETTER

Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist